Naris Nilubol
Overview
Explore the profile of Naris Nilubol including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
161
Citations
2407
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Ghosal S, Hadrava Vanova K, Uher O, Das S, Patel M, Meuter L, et al.
Endocrine
. 2022 Nov;
79(1):171-179.
PMID: 36370152
Purpose: To understand prognostic immune cell infiltration signatures in neuroendocrine neoplasms (NENs), particularly pheochromocytoma and paraganglioma (PCPG), we analyzed tumor transcriptomic data from The Cancer Genome Atlas (TCGA) and other...
22.
Michael N, Nilubol N
Cancers (Basel)
. 2022 Nov;
14(21).
PMID: 36358665
Adrenocortical cancer (ACC) typically presents in advanced stages of disease and has a dismal prognosis. One of the foremost reasons for this is the lack of available systemic therapies, with...
23.
Laha D, Grant R, Mishra P, Boufraqech M, Shen M, Zhang Y, et al.
J Exp Clin Cancer Res
. 2022 Sep;
41(1):282.
PMID: 36151566
Background: Adrenocortical cancer (ACC) is a rare and aggressive cancer with dismal 5-year survival due to a lack of effective treatments. We aimed to identify a new effective combination of...
24.
Graf A, Welch J, Bansal R, Mandl A, Parekh V, Cochran C, et al.
J Endocr Soc
. 2022 Sep;
6(10):bvac122.
PMID: 36111275
Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) may occur in 30% to 90% of patients with multiple endocrine neoplasia type 1 (MEN1). However, only 1% of GEP-NETs are grade 3 (G3). Given the...
25.
Toraih E, Fawzy M, Ning B, Zerfaoui M, Errami Y, Ruiz E, et al.
Cancers (Basel)
. 2022 Sep;
14(17).
PMID: 36077665
Papillary thyroid carcinomas (PTCs) account for most endocrine tumors; however, screening and diagnosing the recurrence of PTC remains a clinical challenge. Using microRNA sequencing (miR-seq) to explore miRNA expression profiles...
26.
Patel M, Jha A, Ling A, Chen C, Millo C, Kuo M, et al.
Cancers (Basel)
. 2022 Aug;
14(16).
PMID: 36010880
The study identifies the importance of positron emission tomographic (PET) and anatomic imaging modalities and their individual performances in detecting succinate dehydrogenase A (-related metastatic pheochromocytoma and paraganglioma (PPGL). The...
27.
Hedges E, Khan T, Babic B, Nilubol N
Am J Surg
. 2022 Aug;
224(5):1256-1261.
PMID: 35999087
Background: Post-operative pancreatic fistula (POPF) is a serious complication following pancreas surgery. We aimed to establish factors associated with POPF specifically in patients with pancreatic neuroendocrine tumors (PNET). Methods: The...
28.
Green B, Grant R, Richie C, Chatterjee B, Sampaio de Melo M, Barr F, et al.
Eur J Endocrinol
. 2022 Jul;
187(1):185-196.
PMID: 35861986
Introduction: Recurrent and metastatic pheochromocytoma (PCC) are rare advanced endocrine neoplasms with limited treatment options. Insight into the pathogenic molecular alterations in patients with advanced PCC can provide therapeutic options...
29.
30.
Mishra P, Laha D, Grant R, Nilubol N
Cancers (Basel)
. 2021 Dec;
13(24).
PMID: 34944814
Thyroid cancer is the most common type of endocrine malignancy comprising 2-3% of all cancers, with a constant rise in the incidence rate. The standard first-line treatments for thyroid cancer...